Human leukemia K562 cells: Relationship between hemin-mediated erythroid induction, cell proliferation and expression of c-abl and c-myc oncogenes

https://doi.org/10.1016/S0006-291X(84)80338-1Get rights and content

We have studied the expression of the c-myc and c-abl oncogenes in two human leukemic K562 cell lines which do express hemoglobin genes retaining a differential rate of cell proliferation. Our data indicate that in hemin-induced K562(S) cells the expression of c-abl oncogene decreases and appears to be related to a decrease in the proliferation capacity rather than to the activation of differentiated functions. The K562(hC) cell line, which produces large amounts of Hb Gower 1 retaining an efficient rate of cell proliferation, expresses indeed the c-abl oncogene at high level.

References (26)

  • HeldinC.H. et al.

    Cell

    (1984)
  • FinkelT. et al.

    Cell

    (1984)
  • HaymanM.J. et al.

    Cell

    (1983)
  • GrossoL.E. et al.

    Biochem.Biophys.Res.Comm.

    (1984)
  • LozzioC.B. et al.

    Blood

    (1975)
  • GambariR. et al.

    Cell Differentiation

    (1984)
  • GambariR. et al.

    Cell Differentiation

    (1983)
  • WhiteB.A. et al.

    J.Biol.Chem.

    (1982)
  • BaralleF.E. et al.

    Cell

    (1980)
  • FantoniA. et al.

    Blood

    (1981)
  • PelicciP.G. et al.

    FEBS Letters

    (1982)
  • DownwardJ. et al.

    Nature

    (1984)
  • BishopJ.M.

    Ann.Rev.Biochem.

    (1983)
  • Cited by (17)

    • High-level embryonic globin production with efficient erythroid differentiation from a K562 erythroleukemia cell line

      2018, Experimental Hematology
      Citation Excerpt :

      Interestingly, hemin was not required for high-level hemoglobin production in our erythroid differentiation protocol for K562 cells (Fig. 3). Hemin is thought to interfere with cell proliferation with a reduction of BCR/ABL gene expression, resulting in erythroid differentiation of K562 cells [7,27]. The combination of reagents in our protocol might be sufficient for a reduction of BCR/ABL gene (by imatinib) and cell proliferation (by imatinib and rapamycin) to induce erythroid differentiation of K562 cells.

    • Ph positive CML cell lines

      1987, Bailliere's Clinical Haematology
    View all citing articles on Scopus
    View full text